Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Max Gelman

Senior Editor

Arvinas CEO John Houston is planning to retire after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Max Gelman

Senior Editor

Sign up to read this article for free.

Who pays the most in biopharma? We analyzed median pay at 177 companies

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Kidney health biotech emerges with $54M to follow in Vertex’s footsteps

Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet

Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Q&A: Re­tir­ing Arv­inas CEO John Hous­ton talks PRO­TACs, in­vestor con­fi­dence and what’s next with Pfiz­er

Max Gelman

Senior Editor

Sign up to read this article for free.

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Kid­ney health biotech emerges with $54M to fol­low in Ver­tex’s foot­steps

Ul­tragenyx, Mereo’s bone dis­ease drug fails sec­ond in­ter­im analy­sis, stocks plum­met

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

Who pays the most in biopharma? We analyzed median pay at 177 companies

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Kidney health biotech emerges with $54M to follow in Vertex’s footsteps

Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet

Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases